Hassoba, H., Saleh, R. (2013). Interleukin-18 in Health and Disease. Suez Canal University Medical Journal, 16(2), 78-86. doi: 10.21608/scumj.2013.54218
Howayda M Hassoba; Rania M Saleh. "Interleukin-18 in Health and Disease". Suez Canal University Medical Journal, 16, 2, 2013, 78-86. doi: 10.21608/scumj.2013.54218
Hassoba, H., Saleh, R. (2013). 'Interleukin-18 in Health and Disease', Suez Canal University Medical Journal, 16(2), pp. 78-86. doi: 10.21608/scumj.2013.54218
Hassoba, H., Saleh, R. Interleukin-18 in Health and Disease. Suez Canal University Medical Journal, 2013; 16(2): 78-86. doi: 10.21608/scumj.2013.54218
Department of Clinical Pathology, Faculty of Medicine, Suez Canal University
Abstract
Interleukin-18 (IL-18) is a relatively newly discovered immunostimulatory cytokine, which is structurally similar to IL-1. IL-18 is produced mainly by activated macrophages, however; it may also be expressed by kupffer cells, T cells, B cells, keratinocytes, astrocytes, and osteoblasts. IL-18 can regulate both innate and adaptive immune responses through its effects on natural killer (NK) cells, monocytes, dendritic cells, T cells, and B cells. IL-18 has multiple biological activities via its capacity to stimulate innate immunity and both Th1 and Th2 mediated responses. IL-18 acts synergistically with other pro-inflammatory cytokines to promote interferon-γ (IFN-γ) production by NK cells, T cells, and possibly other cell types. It induces gene expression and synthesis of Tumor Necrosis Factor (TNF), IL-1, Fas Ligand, and several chemokines. It also exerts anti-tumor effects that are mediated by enhancement of Natural Killer (NK) cell activity, reduction of tumorigenesis, induction of apoptosis and inhibition of angiogenesis in tumor cells. IL-18 plays a critical role in the Th1 response required for host defense against viruses as well as plays a role in inflammatory liver disease. IL-18 was significantly upregulated in persons with chronic HCV infection compared to healthy persons or asymptomatic carriers. This upregulation correlated with hepatic injury, indicating a role for IL-18 in the pathogenesis of HCV infection. In addition, neutralization of IL-18 by administration of anti-IL-18 monoclonal antibodies (mAb) results in total prevention of liver injury. Raised levels of serum IL-18 was demonstrated in chronic HCV-patients before antiviral therapy with Pegylated IFN (PEG-IFN). A marked decline in IL-18 was associated with remission of hepatic inflammatory activity in responders, while persistent raised levels of IL-18 were associated with PEG-IFN treatment failure.
View on SCiNiTO
Top